A Case of Rapidly Progressive Pneumonitis Induced by Nivolumab in Metastatic Gastroesophageal Adenocarcinoma: Challenges in Diagnosis and Management.
1/5 보강
Immune checkpoint inhibitors like nivolumab have transformed cancer therapy but are associated with immune-related, sometimes life-threatening, adverse events, including pneumonitis.
APA
Datta N, Vieira AC, Strait C (2025). A Case of Rapidly Progressive Pneumonitis Induced by Nivolumab in Metastatic Gastroesophageal Adenocarcinoma: Challenges in Diagnosis and Management.. Cureus, 17(10), e94853. https://doi.org/10.7759/cureus.94853
MLA
Datta N, et al.. "A Case of Rapidly Progressive Pneumonitis Induced by Nivolumab in Metastatic Gastroesophageal Adenocarcinoma: Challenges in Diagnosis and Management.." Cureus, vol. 17, no. 10, 2025, pp. e94853.
PMID
41185796 ↗
Abstract 한글 요약
Immune checkpoint inhibitors like nivolumab have transformed cancer therapy but are associated with immune-related, sometimes life-threatening, adverse events, including pneumonitis. We report a case of a 55-year-old man with metastatic gastroesophageal adenocarcinoma who developed rapidly progressive pneumonitis within a week of initiating nivolumab and FOLFOX therapy (folinic acid, 5-fluorouracil and oxaliplatin). Despite some initial improvement with antibiotics and ongoing oral steroids, the patient deteriorated rapidly and died. This case highlights the importance of early recognition and aggressive management of immune-related pneumonitis. Clinicians must be aware of such adverse events, maintain a high index of suspicion and adopt a multidisciplinary approach to optimize outcomes, especially given the often subtle and rapidly evolving clinical presentation.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Advances in IL-15-Based Cancer Immunotherapy and Divergent Immunological Effects of IL-2 and IL-15 Signaling via the Shared IL-2Rβγ Receptor.
- Autophagy Modulation in Cancer Immunotherapy, Emerging Molecular Targets and Drug Selection Strategies.
- Aging modulation of the immune system and immunotherapy efficacy in cancer.
- Interplay between natural killer cells and ferroptosis: novel insights in tumor immunity and therapeutic potential.
- Management Dilemma: Myeloperoxidase (MPO)-Positive Vasculitis in a Patient With Metastatic Malignant Melanoma.